Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments in China, has announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for Cevira (APL-1702) for the treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix, excluding in situ cancer.
APL-1702, a pioneering cold light photodynamic drug-device combination, is used as a non-surgical therapy option for treating cervical HSIL. A Phase III study has shown promising results, demonstrating good efficacy and safety in patients with HSIL.- Flcube.com
